Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

FDA Publishes Two Final Guidances on Technical Specifications for Clinical Data

  • Post author:PacConAdmin
  • Post published:November 6, 2023
  • Post category:Uncategorized

The FDA published a pair of final guidances Friday meant to assist drugmakers by providing technical specifications for submitting general clinical outcome assessment (COA) data and patient-reported outcome (PRO) data…

Continue ReadingFDA Publishes Two Final Guidances on Technical Specifications for Clinical Data

FDA Panel Will Make Classification Recommendations on Blood Irradiators

  • Post author:PacConAdmin
  • Post published:November 6, 2023
  • Post category:Uncategorized

The FDA wants its Radiological Devices Advisory Panel to weigh in on whether irradiators used to prevent metastasis in salvaged blood during cancer surgeries are safe enough to be classified…

Continue ReadingFDA Panel Will Make Classification Recommendations on Blood Irradiators

European Pharma Predicted to Lose a Third of its Global R&D with Proposed Legislation

  • Post author:PacConAdmin
  • Post published:November 6, 2023
  • Post category:Uncategorized

The European Commission’s (EC) proposals to reduce a component of intellectual property protection for breakthrough medicines will hasten a trend which has seen Europe’s position as a global innovator deteriorate…

Continue ReadingEuropean Pharma Predicted to Lose a Third of its Global R&D with Proposed Legislation

Legislative Update — Week of Nov. 6, 2023

  • Post author:PacConAdmin
  • Post published:November 6, 2023
  • Post category:Uncategorized

As the first session of the 118th Congress continues, FDAnews will track important pending legislation, that has been acted on since July 1, to keep you updated on laws and…

Continue ReadingLegislative Update — Week of Nov. 6, 2023

FDA Slaps Natco With Form 483 Over Contamination Issues, Quality Lapses

  • Post author:PacConAdmin
  • Post published:November 3, 2023
  • Post category:Uncategorized

The FDA smacked Natco Pharma for contamination problems and quality control lapses following an inspection of its Rangareddy, Telangana, India facility from Oct. 9 to 18. Source: Drug Industry Daily

Continue ReadingFDA Slaps Natco With Form 483 Over Contamination Issues, Quality Lapses

House and Senate Still Far Apart on FDA Appropriations

  • Post author:PacConAdmin
  • Post published:November 3, 2023
  • Post category:Uncategorized

With the looming expiration of temporary government funding on Nov. 17, lawmakers face significant challenges to reconciling the House and Senate versions of fiscal 2024 appropriations bills — including one…

Continue ReadingHouse and Senate Still Far Apart on FDA Appropriations

Research Round-Up — November 2023

  • Post author:PacConAdmin
  • Post published:November 3, 2023
  • Post category:Uncategorized

This month, FDAnews tackles Amgen’s promising phase 2 study on tarlatamab for SCLC, AbbVie’s Skyrizi and Lilly’s Mirikizumab take on Stelara and 10 year study results for Roche’s Ocrevus for…

Continue ReadingResearch Round-Up — November 2023

How Postpandemic Inspections Could Impact Approvals

  • Post author:PacConAdmin
  • Post published:November 3, 2023
  • Post category:Uncategorized

Many pre-approval inspections that were in limbo because of the backlog during the pandemic are now going ahead and the uptick could result in more product approvals, according to regulatory…

Continue ReadingHow Postpandemic Inspections Could Impact Approvals

Regulatory Update — Week of Oct. 30, 2023

  • Post author:PacConAdmin
  • Post published:November 3, 2023
  • Post category:Uncategorized

Over the past week, the FDA issued final guidances on enforcement for certain supplements for PMA or HDE submissions and clinical electronic thermometers enforcement policy. The agency is also proposing to…

Continue ReadingRegulatory Update — Week of Oct. 30, 2023

Quick Notes for Nov. 2, 2023

  • Post author:PacConAdmin
  • Post published:November 2, 2023
  • Post category:Uncategorized

In this edition of Quick Notes, we cover drug approvals for Roche’s Vabysmo for macular edema, Servier’s Tibsovo for treatment of IDH1, Coherus’ and Shanghai Junshi Biosciences’ Loqtorzi for nasopharyngeal cancer,…

Continue ReadingQuick Notes for Nov. 2, 2023
  • Go to the previous page
  • 1
  • …
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company